Maryland is currently home to 2693 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Open Versus Arthroscopic Stabilization of Shoulder Instability with Subcritical Bone Loss: the OASIS Trial
NCT04809064
Recruiting
This clinical trial will investigate the effects of three surgical procedures and the associated post-operative rehabilitation to optimize time to return to military duty, work and sports, and patient-reported physical function for military personnel and civilians with traumatic anterior shoulder instability and 10-20% glenoid bone loss.
Gender:
ALL
Ages:
Between 17 years and 50 years
Trial Updated:
10/08/2024
Locations: US Naval Health Clinic (Academy), Annapolis, Maryland
Conditions: Shoulder Dislocation, Glenohumeral Dislocation, Anterior Shoulder Dislocation
Register for Updates
Exercise and Nutrition Interventions During Chemotherapy K07
NCT03858153
Recruiting
Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of taxane chemotherapy, often used to treat breast cancer. Unfortunately there are very limited treatments for CIPN. This is a phase II randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on CIPN, to systematically investigate the potential roles of inflammation and interoception, and to obtain data with a more accurate effect size to inform a future study.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Neuropathy;Peripheral
Register for Updates
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
NCT05894876
Recruiting
The study doctor will collect information from participants with Idiopathic Short Stature, who were treated with growth hormone for at least a year when they were children, before they reached puberty. The word "Idiopathic" refers to "unknown cause", and as such the study participants have/had short stature with no identifiable medical cause. The purpose of the study is to identify differences in the genetic characteristics of participants who responded well or poorly to growth hormone therapy.... Read More
Gender:
ALL
Ages:
Between 3 years and 11 years
Trial Updated:
10/07/2024
Locations: Novo Nordisk Investigational Site, Columbia, Maryland
Conditions: Idiopathic Short Stature
Register for Updates
Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
NCT04702243
Recruiting
The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
Gender:
ALL
Ages:
Between 5 years and 45 years
Trial Updated:
10/07/2024
Locations: National Heart, Lung and Blood Institute, Bethesda, Maryland
Conditions: Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome
Register for Updates
An Innovative Intervention for OUD Treatment
NCT04325659
Recruiting
The Bridge Device (BD) is a neuromodulator medical device that has been cleared by the FDA for Opioid Use Disorder (OUD) treatment. Importantly, medical devices reviewed by the FDA are cleared (based on safety) rather than approved (based on efficacy), which means the BD did not need to demonstrate efficacy before it became commercially available. As a result, the device was not required to have a sham-controlled trial for FDA clearance and there is no active research, to the investigators' know... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/07/2024
Locations: Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
Register for Updates
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Johns Hopkins University Hospital, Baltimore, Maryland
Conditions: Giant Cell Tumor of Bone
Register for Updates
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT02910557
Recruiting
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Gender:
ALL
Ages:
All
Trial Updated:
10/04/2024
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Melanoma, Herpetic Infection
Register for Updates
Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Severe Left Diaphragmatic Hernia (CDH)
NCT02710968
Recruiting
Despite advances in prenatal diagnosis and postnatal therapies, including extracorporeal membrane oxygenation (ECMO), inhaled nitric oxide therapy, and ventilator strategies that minimize ventilator-induced lung injury, morbidity and mortality rates for babies with congenital diaphragmatic hernia (CDH) remain high. The survival relates to the degree of prenatal lung compression and the subsequent impairment of pulmonary function following delivery. Prenatal assessment by ultrasound or magnetic r... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Johns Hopkins Center for Fetal Therapy, Baltimore, Maryland
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity
NCT06169150
Recruiting
Background: Immune system and nervous system have significant interaction so that People with immunity diseases can have complications that affect the nervous system and people with some neurological disease may have defects in their immune system.These complications can affect many body functions, including how they move, walk, think, and feel. Researchers do not fully understand how immune diseases affect the nervous system. By learning more, they hope to create more effective treatments. Ob... Read More
Gender:
ALL
Ages:
Between 2 years and 120 years
Trial Updated:
10/03/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Nervous System Disease, Immune System Disease
Register for Updates
Comparing Use of Incentive Spirometry with and Without Reminder
NCT06101030
Recruiting
This study is designed to determine if patients using an incentive spirometer with visual and auditory signals will increase their use of the incentive spirometer and prevent lung complications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Tidal Reseach Site, Silver Spring, Maryland
Conditions: Post Operative
Register for Updates
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, Baltimore, Maryland
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates